FULC
Income statement / Annual
Last year (2023), Fulcrum Therapeutics, Inc.'s total revenue was $2.81 M,
a decrease of 55.77% from the previous year.
In 2023, Fulcrum Therapeutics, Inc.'s net income was -$97.34 M.
See Fulcrum Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$2.81 M
|
$6.34 M
|
$19.16 M
|
$8.82 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$71.80 M |
$2.41 M |
$2.52 M |
$2.38 M |
$2.05 M |
$1.35 M |
$715,000.00 |
| Gross Profit |
-$69.00 M |
$3.93 M |
$16.65 M |
$6.44 M |
-$2.05 M |
-$1.35 M |
-$715,000.00 |
| Gross Profit Ratio |
-24.6 |
0.62 |
0.87 |
0.73 |
0 |
0 |
0 |
| Research and Development
Expenses |
$71.80 M
|
$76.78 M
|
$69.70 M
|
$59.04 M
|
$71.07 M
|
$25.18 M
|
$18.49 M
|
| General & Administrative
Expenses |
$41.67 M
|
$41.69 M
|
$30.52 M
|
$21.39 M
|
$13.15 M
|
$8.31 M
|
$4.50 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$41.67 M
|
$41.69 M
|
$30.52 M
|
$21.39 M
|
$13.15 M
|
$8.31 M
|
$4.50 M
|
| Other Expenses |
$0.00 |
$2.69 M |
$207,000.00 |
$792,000.00 |
$29,000.00 |
$392,000.00 |
$28,000.00 |
| Operating Expenses |
$113.47 M |
$118.48 M |
$100.22 M |
$80.43 M |
$84.22 M |
$33.50 M |
$22.99 M |
| Cost And Expenses |
$113.47 M |
$118.48 M |
$100.22 M |
$80.43 M |
$84.22 M |
$33.50 M |
$22.99 M |
| Interest Income |
$0.00 |
$2.69 M |
$207,000.00 |
$792,000.00 |
$1.51 M |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$2.69 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$2.17 M
|
$2.41 M
|
$2.52 M
|
$2.38 M
|
$2.05 M
|
$1.35 M
|
$715,000.00
|
| EBITDA |
-$108.49 M
|
-$109.72 M
|
-$78.54 M
|
-$69.23 M
|
-$82.16 M
|
-$32.15 M
|
-$22.28 M
|
| EBITDA Ratio |
-38.68 |
-17.61 |
-4.23 |
-8.12 |
0 |
0 |
0 |
| Operating Income Ratio
|
-39.45
|
-17.75
|
-4.23
|
-8.12
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$13.33 M
|
$2.69 M
|
$207,000.00
|
$792,000.00
|
$1.54 M
|
$910,000.00
|
$29,000.00
|
| Income Before Tax |
-$97.34 M |
-$109.87 M |
-$80.85 M |
-$70.82 M |
-$82.68 M |
-$32.59 M |
-$22.96 M |
| Income Before Tax Ratio
|
-34.7
|
-17.32
|
-4.22
|
-8.03
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$4.25 M |
-$2.52 M |
-$2.38 M |
-$3.56 M |
$910,000.00 |
-$1,000.00 |
| Net Income |
-$97.34 M |
-$105.62 M |
-$78.33 M |
-$68.44 M |
-$79.11 M |
-$32.59 M |
-$22.96 M |
| Net Income Ratio |
-34.7 |
-16.65 |
-4.09 |
-7.76 |
0 |
0 |
0 |
| EPS |
-1.59 |
-2.35 |
-2.22 |
-2.7 |
-7.16 |
-1.92 |
-2.1 |
| EPS Diluted |
-1.59 |
-2.35 |
-2.22 |
-2.7 |
-7.16 |
-1.92 |
-2.1 |
| Weighted Average Shares
Out |
$61.31 M
|
$44.99 M
|
$35.36 M
|
$25.35 M
|
$11.05 M
|
$16.94 M
|
$10.95 M
|
| Weighted Average Shares
Out Diluted |
$61.31 M
|
$44.99 M
|
$35.36 M
|
$25.35 M
|
$11.05 M
|
$16.94 M
|
$10.95 M
|
| Link |
|
|
|
|
|
|
|
